Edition:
United States

Incyte Corp (INCY.OQ)

INCY.OQ on NASDAQ Stock Exchange Global Select Market

105.47USD
17 Nov 2017
Change (% chg)

$-1.01 (-0.95%)
Prev Close
$106.48
Open
$106.06
Day's High
$107.00
Day's Low
$105.42
Volume
441,101
Avg. Vol
539,962
52-wk High
$153.14
52-wk Low
$98.56

Select another date:

Wed, Nov 15 2017

BRIEF-Incyte initiates clinical trial of Ruxolitinib for treatment of essential thrombocythemia

* Incyte announces initiation of pivotal clinical trial of Ruxolitinib (Jakafi®) for the treatment of essential thrombocythemia

BRIEF-Incyte says Q3 earnings per share $0.17

* Incyte reports 2017 third-quarter financial results and updates on key clinical programs

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

AstraZeneca plans new pivotal lung cancer trial with Incyte

LONDON, Oct 31 AstraZeneca is stepping up its bet on immunotherapy combination treatments to fight lung cancer by signing a deal with Incyte under which the two companies will start a final-stage Phase III clinical trial next year.

BRIEF-Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer

* Incyte and AstraZeneca to enter clinical trial collaboration in early lung cancer

BRIEF-Incyte Corp names new member to its board of directors

* Incyte names new member to its board of directors Source text for Eikon: Further company coverage:

BRIEF-Incyte and MacroGenics announce global collaboration and licensing agreement

* Incyte and MacroGenics announce global collaboration and licensing agreement for Anti-PD-1 Monoclonal Antibody MGA012

BRIEF-Concert Pharma Says PTAB denies Incyte petition challenging CTP-543 patent

* Concert Pharma says patent trials and appeal board of u.s. patent and trademark office has denied Incyte's petition to institute IPR​ Source text for Eikon: Further company coverage:

BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

* Baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis

BRIEF-Incyte announces pricing of public offering of 4,945,000 shares

* Incyte announces pricing of public offering of 4,945,000 shares of common stock Source text for Eikon: Further company coverage:

Select another date: